FDA lets drug makers go digital-first on prescribing info—but doctors must ask for paper
S. 5242 — Prescription Information Modernization Act of 2026 · Filed by Jim Banks (R-IN) · 1 cosponsor · Introduced Aug 4, 2026 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill allows pharmaceutical manufacturers to provide prescribing information to doctors and pharmacists electronically instead of on paper, but requires them to offer paper copies upon request at no cost. The FDA must issue regulations within one year to implement this change and ensure healthcare professionals can still access paper versions if they prefer, with an effective date of 2 years after enactment or when final rules are issued, whichever comes first.
Why we flagged it
The bill's core function is to modernize how drug prescribing information is delivered—shifting from paper-default to digital-default—while preserving paper access on demand. This is a regulatory efficiency measure that primarily benefits manufacturers by reducing printing and distribution costs.
What the text implies
- Manufacturers gain cost savings from reduced paper printing and distribution, which may not be passed to consumers or healthcare systems.
- Prescribers and dispensers with limited digital infrastructure or those serving populations with poor digital access may face practical barriers to obtaining paper copies promptly.
The full analysis lists 4 implications of this text.
Who stands to gain
pharmaceutical manufacturers; drug distributors; digital health information platforms